GLOBUS MEDICAL INC
GMEDNYSE
$77.00
↓ -4.8%Jul 17 close · end-of-day
Price
1Y↑ +36.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$10.6B
Enterprise Value
$10.0B
P/E
18.0
P/S
3.4
P/B
2.2
EV/EBITDA
12.3
PEG
0.6
FCF Yield
5.7%
Dividend Yield
—
Revenue (TTM)
$3.1B
Net Income (TTM)
$586.7M
Free Cash Flow (TTM)
$610.3M
Gross Margin
—
Operating Margin
17.2%
Net Margin
18.9%
ROE
12.4%
ROIC
11.6%
Debt / Equity
—
Net Cash
$629.9M
Return 1Y
+33.8%
Company profile
Globus Medical, Inc. develops and commercializes healthcare solutions for musculoskeletal disorders in the United States and internationally. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, external fixation systems.
- CEO
- Daniel T. Scavilla
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 2,600
- Headquarters
- Pennsylvania
- Website
- globusmedical.com
Management & directors
- Huller KellyEVP, GC, Corporate Secretary
- Kline KyleSenior Vice President, CFO
- Paul David CExecutive Chairman
Roles derived from SEC Form 4 filings.
Earnings
GMED Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$759.9M↑ +27.0%
Diluted EPS$0.90↑ +66.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $789.0M | $958.1M | $1.0B | $1.6B | $2.5B | $2.9B |
| Gross profit | $571.6M | $718.9M | $759.1M | $1.0B | — | — |
| Operating income | $111.4M | $172.0M | $228.0M | $133.1M | $166.0M | $479.8M |
| Net income | $102.3M | $149.2M | $190.2M | $122.9M | $103.0M | $537.9M |
| Diluted EPS | $1.01 | $1.44 | $1.85 | $1.07 | $0.75 | $3.92 |
| Operating cash flow | $198.8M | $276.3M | $178.5M | $243.5M | $520.6M | $753.4M |
| Free cash flow | $135.1M | $219.4M | $104.4M | $165.2M | $405.2M | $588.8M |
| Gross margin | 72.4% | 75.0% | 74.2% | 65.1% | — | — |
| Operating margin | 14.1% | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% |
| Net margin | 13.0% | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $629.7M | $625.7M | $657.3M | $598.1M | $745.3M | $769.0M | $826.4M | $759.9M |
| Gross profit | $369.7M | — | — | — | — | — | — | — |
| Operating income | $49.6M | $48.1M | $60.3M | $97.0M | $76.1M | $137.4M | $169.3M | $150.4M |
| Net income | $31.8M | $51.8M | $26.5M | $75.5M | $202.8M | $119.0M | $140.6M | $124.3M |
| Diluted EPS | $0.23 | $0.38 | $0.19 | $0.54 | $1.49 | $0.88 | $1.01 | $0.90 |
| Operating cash flow | $54.3M | $203.7M | $210.3M | $177.3M | $77.9M | $249.7M | $248.6M | $202.4M |
| Free cash flow | $26.5M | $161.7M | $193.2M | $141.2M | $31.3M | $213.9M | $202.4M | $162.7M |
| Gross margin | 58.7% | — | — | — | — | — | — | — |
| Operating margin | 7.9% | 7.7% | 9.2% | 16.2% | 10.2% | 17.9% | 20.5% | 19.8% |
| Net margin | 5.0% | 8.3% | 4.0% | 12.6% | 27.2% | 15.5% | 17.0% | 16.4% |
Company news
Jul 20, 2026
Jul 17, 2026
Jul 16, 2026
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-05 | Davidar David D | Sale | 25,000 | $80.76 | $2.0M | filing |
| 2026-06-05 | Davidar David D | Option exercise | 25,000 | $26.27 | $656,750.00 | filing |
| 2026-06-04 | RHOADS ANN D | Option exercise | 25,000 | $26.27 | $656,750.00 | filing |
| 2026-02-25 | Huller Kelly· EVP, GC, Corporate Secretary | Sale | 20,000 | $94.50 | $1.9M | filing |
| 2026-02-25 | Huller Kelly· EVP, GC, Corporate Secretary | Option exercise | 20,000 | $43.58 | $871,600.00 | filing |
| 2026-02-12 | Huller Kelly· EVP, GC, Corporate Secretary | Sale | 10,000 | $87.67 | $876,700.00 | filing |
| 2026-02-12 | Huller Kelly· EVP, GC, Corporate Secretary | Option exercise | 10,000 | $45.64 | $456,400.00 | filing |
| 2026-01-08 | Kline Kyle· Senior Vice President, CFO | Sale | 3,594 | $101.10 | $363,353.40 | filing |
| 2026-01-08 | Norwalk Leslie V | Sale | 2,000 | $101.10 | $202,200.00 | filing |
| 2026-01-08 | Kline Kyle· Senior Vice President, CFO | Option exercise | 3,594 | $51.87 | $186,420.78 | filing |
| 2025-12-12 | Norwalk Leslie V | Sale | 4,000 | $88.85 | $355,400.00 | filing |
| 2025-12-08 | Paul David C· Executive Chairman | Option exercise | 34,375 | $25.52 | $877,250.00 | filing |
| 2025-12-01 | Kline Kyle· Senior Vice President, CFO | Sale | 18,542 | $90.00 | $1.7M | filing |
| 2025-12-01 | Kline Kyle· Senior Vice President, CFO | Option exercise | 5,000 | $64.44 | $322,200.00 | filing |
| 2025-12-01 | Kline Kyle· Senior Vice President, CFO | Option exercise | 4,896 | $63.68 | $311,777.28 | filing |
| 2025-12-01 | Kline Kyle· Senior Vice President, CFO | Option exercise | 5,000 | $56.43 | $282,150.00 | filing |
| 2025-12-01 | Kline Kyle· Senior Vice President, CFO | Option exercise | 3,646 | $53.14 | $193,748.44 | filing |
| 2025-11-25 | Huller Kelly· SVP, GC, Corporate Secretary | Sale | 7,500 | $90.00 | $675,000.00 | filing |
| 2025-11-25 | Huller Kelly· SVP, GC, Corporate Secretary | Option exercise | 7,500 | $25.96 | $194,700.00 | filing |
| 2025-11-12 | Davidar David D | Sale | 25,000 | $86.00 | $2.2M | filing |
| 2025-11-12 | Davidar David D | Option exercise | 25,000 | $25.52 | $638,000.00 | filing |
| 2025-11-11 | ZARRILLI STEPHEN T | Sale | 25,000 | $84.29 | $2.1M | filing |
| 2025-11-11 | ZARRILLI STEPHEN T | Option exercise | 25,000 | $44.14 | $1.1M | filing |
| 2025-11-10 | RHOADS ANN D | Sale | 2,000 | $85.00 | $170,000.00 | filing |
| 2025-11-07 | RHOADS ANN D | Sale | 8,000 | $81.00 | $648,000.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.